Goldman Sachs Discloses Passive Stake in bluebird bio
Ticker: GSCE · Form: SC 13G · Filed: Feb 6, 2024 · CIK: 886982
| Field | Detail |
|---|---|
| Company | Goldman Sachs Group INC (GSCE) |
| Form Type | SC 13G |
| Filed Date | Feb 6, 2024 |
| Risk Level | low |
| Sentiment | bullish |
Complexity: simple
Sentiment: bullish
Topics: institutional-ownership, passive-investment, biotech
TL;DR
**Goldman Sachs just revealed a stake in bluebird bio, signaling institutional interest.**
AI Summary
Goldman Sachs Group Inc. filed an SC 13G on February 6, 2024, disclosing its ownership of bluebird bio, Inc. common stock as of December 29, 2023. This filing indicates that Goldman Sachs holds a significant, though passive, stake in the biotechnology company. This matters to investors because it signals that a major financial institution sees value in bluebird bio, potentially boosting investor confidence in the stock.
Why It Matters
A large institutional investor like Goldman Sachs taking a position can be seen as a vote of confidence, potentially attracting other investors and influencing the stock price positively.
Risk Assessment
Risk Level: low — This filing is a routine disclosure of a passive investment, not indicating any immediate high-risk event.
Analyst Insight
A smart investor would view this as a positive signal, potentially researching bluebird bio further to understand the underlying reasons for Goldman Sachs's investment, but would not make a decision based solely on this filing.
Key Players & Entities
- GOLDMAN SACHS GROUP INC (company) — filer of the SC 13G
- bluebird bio, Inc. (company) — subject company in which shares are held
- December 29, 2023 (date) — date of event requiring the filing
- February 6, 2024 (date) — filing date of the SC 13G
- $0.01 (dollar_amount) — par value per share of bluebird bio common stock
Forward-Looking Statements
- bluebird bio's stock price may see a short-term positive reaction due to institutional interest. (bluebird bio, Inc.) — medium confidence, target: 1-3 months
- Goldman Sachs will maintain its passive stake in bluebird bio for the foreseeable future. (GOLDMAN SACHS GROUP INC) — high confidence, target: 6-12 months
FAQ
What type of filing is this document?
This document is an SC 13G filing, specifically designated under Rule 13d-1(b), which is used by passive institutional investors.
Who is the filer of this SC 13G?
The filer of this SC 13G is GOLDMAN SACHS GROUP INC, with CIK 0000886982.
Which company's shares are the subject of this filing?
The subject company is bluebird bio, Inc., identified by CIK 0001293971, and the filing concerns its Common Stock, par value $0.01 per share.
What was the 'Date of Event Which Requires Filing of this Statement'?
The 'Date of Event Which Requires Filing of this Statement' was December 29, 2023.
What is the CUSIP number for bluebird bio, Inc. common stock mentioned in the filing?
The CUSIP number for bluebird bio, Inc. common stock is 09609G100.
Filing Details
This Form SC 13G (Form SC 13G) was filed with the SEC on February 6, 2024 regarding GOLDMAN SACHS GROUP INC (GSCE).